SavedAdd your journal

Journals / Türk Osteoporoz Dergisi / 2016 / Cilt: 22 - Sayı: 3

Remarkable Hematological Laboratory Findings in Patients with Fibromyalgia Syndrome

Fibromiyalji Sendromunda Dikkat Çeken Hematolojik Laboratuvar Değerleri

Selçuk SAYILIR
Pages
121–124
Publication Date
2022-11-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Patients not having hypertension, hypercholesterolaemia or diabetes, chronic inflammatory disease, history of thrombotic disease or not receiving anticoagulant agents, and as well as patients having body mass index of

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In our study, we examined the role of mean platelet volume (MPV) and red blood cell distribution width (RDW) values with certain laboratory findings in Fibromyalgia syndrome (FMS).
📊
Key Findings & Data:This study is the first study which evaluates the relationship between MPV and RDW values in FMS patients.Materials and Methods: The study consisted of two groups; study group (n=36; FMS patients) and control group (n=36).
💡
Conclusion & Impact:Patients not having hypertension, hypercholesterolaemia or diabetes, chronic inflammatory disease, history of thrombotic disease or not receiving anticoagulant agents, and as well as patients having body mass index of
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: In our study, we examined the role of mean platelet volume (MPV) and red blood cell distribution width (RDW) values with certain laboratory findings in Fibromyalgia syndrome (FMS). This study is the first study which evaluates the relationship between MPV and RDW values in FMS patients.Materials and Methods: The study consisted of two groups; study group (n=36; FMS patients) and control group (n=36). Patients not having hypertension, hypercholesterolaemia or diabetes, chronic inflammatory disease, history of thrombotic disease or not receiving anticoagulant agents, and as well as patients having body mass index of

Özet

Amaç: Çalışmamızda ortalama trombosit hacmi (OTH) ve eritrosit dağılım genişliği (EDG) değerleri ile beraber bazı laboratuvar bulgularının Fibromiyalji sendromu (FMS) ile ilişkisi incelendi. Çalışmamız FMS'de OTH ve EDG değerlerinin beraber değerlendirildiği ilk çalışma olma özelliğini taşımaktadır.Gereç ve Yöntem: Çalışmaya hipertansiyonu, hiperkolesterolemisi veya diyabeti, kronik enflamatuvar hastalıkları, trombotik hastalık öyküsü veya antikoagülan tedavi kullanımı olmayan ve vücut kitle indeksleri 30 kg/m2'nin altında olan 36 FMS hastası ve 36 kişilik kontrol grubu dahil edildi. Bilgisayar tabanlı yazılımlarla retrospektif olarak veriler incelendi.Bulgular: Çalışmaya dahil edilen 36 FMS hastasının yaş ortalamaları 44,6, kontrol grubunun yaş ortalaması 42,5 olarak bulundu. Hemoglobin, hematokrit, ortalama eritrosit hacmi, platelet sayısı, EDG, OTH değerleri gruplar arasında istatistiksel anlamlı fark göstermedi. Öte yandan EDG değerlerinin iki grup arasında sınırda istatistiksel anlam taşıdığı görüldü.Sonuç: Çalışmamız sonucunda, OTH değerlerinin gruplar arasında istatistiksel fark göstermemesine rağmen EDG değerlerinin sınıra yakın istatistiksel fark göstermesinin akılda tutulmasının, klinik pratikte faydalı olacağı kanaati oluşmuştur.

🔖

Cite This Article

SAYILIR, S. (2022). Remarkable Hematological Laboratory Findings in Patients with Fibromyalgia Syndrome. Türk Osteoporoz Dergisi, Cilt: 22 - Sayı: 3, 121–124. https://ajindex.com/articles/639742

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. Williams DA, Clauw DJ. Understanding fibromyalgia: lessons from the broader pain research community. J Pain 2009;10:777- 91. Branco JC, Bannwarth B, Failde I, Abello Carbonell J, Blotman F, Spaeth M, et al. Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum 2010;39:448-53.
  2. Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord 2007;8:27. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160- 72. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010;62:600- 10. Clauw DJ. Fibromyalgia: an overview. Am J Med 2009;122:S3- S13. Bellato E, Marini E, Castoldi F, Barbasetti N, Mattei L, Bonasia DE, et al. Fibromyalgia syndrome: etiology, pathogenesis, diagnosis, and treatment. Pain Res Treat 2012;2012:426130. Rozanski A. Integrating psychologic approaches into the behavioral management of cardiac patients. Psychosom Med 2005;67(Suppl 1):S67-73. Miller MA. Association of inflammatory markers with cardiovascular risk and sleepiness. J Clin Sleep Med 2011;7:S31-3. Klovaite J, Benn M, Yazdanyar S, Nordestgaard BG. High platelet volume and increased risk of myocardial infarction: 39,531 participants from the general population. J Thromb Haemost 2011;9:49-56.
  3. Yilmaz H, Ertugrul O, Ertugrul B, Ertugrul D. Mean platelet volume in patients with subclinical hypothyroidism. Platelets 2011;22:143- 7. Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Konkle B, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost 2010;8:148-56.
  4. Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des 2011;17:47-58.
  5. Bavbek N, Kargili A, Kaftan O, Karakurt F, Kosar A, Akcay A. Elevated concentrations of soluble adhesion molecules and large platelets in diabetic patients: are they markers of vascular disease and diabetic nephropathy? Clin Appl Thromb Hemost 2007;13:391-7.
  6. Mutlu H, Berk V, Karaca H, Erden A, Aslan T, Akca Z. Treatment regimen with bevacizumab decreases mean plat